Clinical trial
DOXIL for Consolidation Therapy in Ovarian Cancer.
NCT00248248 · Southeastern Gynecologic Oncology, Other · Completed
Key facts
| NCT number | NCT00248248 |
|---|---|
| Title | DOXIL for Consolidation Therapy in Ovarian Cancer. |
| Official title | A Phase II Non-randomized Study of DOXIL Consolidation Treatment for Ovarian Cancer, Cancer of the Fallopian Tube or Peritoneal Carcinoma. |
| Lead sponsor | Southeastern Gynecologic Oncology, Other |
| Collaborators | Ortho Biotech, Inc. Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Ovarian Neoplasm |
| Intervention type | Drug |
| Interventions | liposomal doxorubicin |
| Enrollment | 45 |
| Start date | Oct 1, 2005 |
| Primary completion | Oct 1, 2011 |
| Completion | Oct 1, 2011 |
| First posted | Nov 3, 2005 |
| Last update posted | Oct 12, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: